GlassScriptPhysician profile
Antonios Christou
NPI 1922044098
$261.09
in general payments reported to CMS, 2019-2025
12 companies · $36.58 in 2025
The $36.58 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.17 · 2020: $95.00 · 2021: $36.89 · 2024: $70.45 · 2025: $36.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $107.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $95.00 | 2020 | |
| Caris Mpi, INC. | $22.17 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $22.17 | 2019 | |
| Pfizer INC. | $20.72 | 2024 | |
| Tempus Ai, INC | $17.01 | 2024 | |
| Array Biopharma INC | $16.45 | 2024 | Lorbrena, Mektovi, Braftovi |
| Novartis Pharmaceuticals Corporation | $16.27 | 2024 | |
| Beone Medicines USA, INC. | $14.41 | 2025 | Tevimbra |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonios Christou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.